Hoth Therapeutics Deploys OpenAI API for Rare KIT-Driven Cancer Therapy Development

Hoth Therapeutics has integrated the OpenAI API into its development workflow for HT-KIT, a therapy targeting rare and aggressive KIT-driven cancers. The API has supported preclinical data analysis, molecular modeling, and regulatory documentation preparation. HT-KIT has shown potent gene-level target suppression and favorable tolerability in early studies. The company aims to submit an IND for HT-KIT.